Literature DB >> 15028966

The spectrum of cardiovascular infections due to Salmonella enterica: a review of clinical features and factors determining outcome.

Manuel L Fernández Guerrero1, José Maria Aguado, Ana Arribas, Carlos Lumbreras, Miguel de Gorgolas.   

Abstract

Cardiovascular infections due to Salmonella enterica are infrequently reported, so their clinical features, prognosis, and optimal treatment are not completely known. Mortality associated with aortitis and endocarditis caused by nontyphoidal Salmonella remains exceedingly high. In this review of cases of cardiovascular infections due to Salmonella enterica studied in 2 hospitals in Madrid, we tried to assess the clinical manifestations and the procedures leading to diagnosis in addition to treatment and outcome. To complete the spectrum of infections related to cardiovascular surgery, cases of postoperative mediastinitis, pericarditis, and infections associated with cardiac devices were also included.Twenty-three patients were reviewed: 11 had mycotic aneurysms; 7 had endocarditis; 2 had device-related infections; and 3 had pericarditis, mediastinitis, and infection of an arteriovenous fistula, respectively. The risk of endovascular infection in patients older than 60 years with bacteremia due to nontyphoidal Salmonella was 23%. Most patients with aortitis had risk factors for atherosclerosis, and 6 had preexisting atherosclerotic aortic aneurysms. All except 1 patient with endocarditis had underlying cardiac disorders. Acquired immunodeficiency disease (AIDS) was a major risk factor for salmonella bacteremia in 1 patient with aortitis and 1 with endocarditis. Fever, unremitting sepsis, "breakthrough" and relapsing bacteremia were the most common clinical findings. In addition, abdominal or thoracic pain and cardiac failure and pericarditis were common features in patients with aortitis and endocarditis respectively. Computed tomography (CT) scan, arteriography, and echocardiography were the main diagnostic tools. Mortality associated with mycotic aneurysms and endocarditis due to S. enterica was 45% and 28%, respectively. Thoracic aneurysms, rupture, and shock at the time of diagnosis were associated with increased mortality in patients with aortitis. In situ bypass grafting was successfully performed in most cases. After surgery, antimicrobial therapy was continued for 4-9 weeks. No relapses were observed after a mean follow-up of 64 months. Antimicrobial therapy alone or combined with valve replacement or excision of a ventricular aneurysm was successful treatment for most patients with salmonella endocarditis. Combined medical and surgical treatment was required for patients with mediastinitis and pericarditis, and patients with device-related infections needed removal of the complete device. Diagnosis of aortitis due to nontyphoidal Salmonella should be established as early as possible to reduce mortality. Patients older than 60 years who have positive blood cultures for Salmonella along with fever and back, abdominal, or chest pain should have an extensive workup for infective aortitis. Immediate bactericidal antimicrobial therapy should be started and a CT scan should be performed on an emergency basis. If a mycotic aneurysm is found, surgical resection should follow as soon as possible. Resection of the aneurysm with in situ bypass grafting is the procedure of choice. Postoperative antimicrobial therapy for 6-8 weeks seems enough to avoid relapses. Optimal treatment of patients with endocarditis occurring on ventricular aneurysms must include resection of the aneurysmal sac. Salmonella endocarditis can be successfully treated with antimicrobials alone. Valve replacement should be reserved for patients with cardiac failure or persisting sepsis, and for those who relapse after discontinuation of antimicrobial therapy.

Entities:  

Mesh:

Year:  2004        PMID: 15028966     DOI: 10.1097/01.md.0000125652.75260.cf

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  29 in total

1.  Global trends in infective endocarditis epidemiology.

Authors:  Haur Sen Yew; David R Murdoch
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

2.  Salmonella enterica cholerasuis bacteremia and mycotic aneurysm of abdominal aorta in a hemodialysis patient.

Authors:  Yao-Min Hung
Journal:  Intensive Care Med       Date:  2005-07-29       Impact factor: 17.440

Review 3.  Aortitis.

Authors:  Heather L Gornik; Mark A Creager
Journal:  Circulation       Date:  2008-06-10       Impact factor: 29.690

4.  Gram-negative endocarditis.

Authors:  Milagros P Reyes; Katherine C Reyes
Journal:  Curr Infect Dis Rep       Date:  2008-07       Impact factor: 3.725

Review 5.  Aortitis - An Interdisciplinary Challenge.

Authors:  Tetyana Shchetynska-Marinova; Klaus Amendt; Maliha Sadick; Michael Keese; Martin Sigl
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

6.  Infected aneurysm.

Authors:  Kamphol Laohapensang; Robert B Rutherford; Supapong Arworn
Journal:  Ann Vasc Dis       Date:  2010-07-21

Review 7.  Nontyphoidal cardiac salmonellosis: two case reports and a review of the literature.

Authors:  Daniel Ortiz; Eric M Siegal; Christopher Kramer; Bijoy K Khandheria; Ernesto Brauer
Journal:  Tex Heart Inst J       Date:  2014-08-01

8.  Bacteraemia due to ciprofloxacin-resistant Salmonella enterica serotype Choleraesuis in adult patients at a university hospital in Taiwan, 1996-2004.

Authors:  J-Y Wang; J-J Hwang; C-N Hsu; L-C Lin; P-R Hsueh
Journal:  Epidemiol Infect       Date:  2006-03-29       Impact factor: 2.451

9.  Infectious Aortitis.

Authors:  Elizabeth A Foote; Russell G Postier; Ronald A Greenfield; Michael S Bronze
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-06

Review 10.  Infective endocarditis caused by Salmonella enteritidis in a dialysis patient: a case report and literature review.

Authors:  Yusuke Tsugawa; Miyuki Futatsuyama; Keiichi Furukawa; Fumika Taki; Yuji Nishizaki; Keiichi Tamagaki; Yuki Kaneshiro; Yasuhiro Komatsu
Journal:  BMC Infect Dis       Date:  2009-09-29       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.